AMiAware Cardiac Panel
Risk prediction and prognosis of Impending Heart Attack / Acute Coronary Syndromes
Key Facts
About XCellCure
XCellCure is a private, commercial-stage diagnostics company headquartered in St. Louis, Missouri, with a mission to transform the treatment of acute coronary syndromes. Its core product, the AMiAware Cardiac Panel, is a multiplexed diagnostic test designed to non-invasively identify patients at high risk for a heart attack, allowing for timely, personalized therapeutic intervention. The company targets the significant unmet need in preventing first and fatal heart attacks, aiming to move acute cardiovascular care into the realm of precision medicine. XCellCure appears to be in an early revenue-generating phase, commercializing its patented prognostic markers to clinics and healthcare providers.
View full company profile